Heart transplantation in patients over 54 years of age with triple-drug therapy immunosuppression.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

PubMedID: 1420241

Fabbri A, Sharples LD, Mullins P, Caine N, Large S, Wallwork J. Heart transplantation in patients over 54 years of age with triple-drug therapy immunosuppression. J Heart Lung Transplant. 1992;11(5):929-32.
Between April 1, 1986, and December 31, 1989, 206 patients received orthotopic heart transplants with triple-drug therapy immunosuppression (cyclosporine, azathioprine, prednisone). Forty-six patients were aged 55 years or more at the time of transplantation and 160 patients were less than 55 years of age; these two groups were compared. Selection criteria and treatment regimen were the same in both groups. In our experience, although both groups had good postoperative survival, older patients had higher mortality rates early after transplantation, particularly from rejection and infection. Patients over 55 years of age had similar nonfatal rejection rates and were no more likely to have infectious episodes than younger patients. As demand for heart transplantation increases and waiting lists lengthen, the age of potential recipients should be an important factor in deciding how to allocate scarce donated organs, although age should not be exclusive.